Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
U.S. FDA to decide whether to authorize a booster dose in the coming days
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
